Leaked political proposals to stop German insurance funds awarding tender contracts to just one supplier would not help to prevent drug shortages, insists the leading AOK group of funds.

Teva’s Actavis has lost the patent battle over osteoarthritis drug Pennsaid 2% due to a lack of “clear and convincing evidence” and “unpersuasive arguments” over obviousness.

A German higher regional court has upheld an injunction barring Mylan from marketing its Clift rival to Teva’s Copaxone 40mg/ml multiple sclerosis treatment.

Having unsuccessfully asserted a patent under the previous legal framework in Canada does not preclude an originator from trying again following legislative amendments enacted in 2017, the country’s Federal Court of Appeal has ruled in a decision on Pfizer’s Nivestym filgrastim biosimilar.

Originators that make discounts on biologic list prices conditional on hospitals not switching treatment to anti-TNF biosimilars may be breaching competition law, the Netherlands’ competition authority is warning.

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

Recognizing the benefits of value added medicines in European hospital settings can help patients and healthcare professionals, a KPMG report commissioned by Medicines for Europe suggests.